获得初级保健设施的结核病患者的高死亡率:来自一项开放标签聚类随机试验的二次分析

IF 9.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
EClinicalMedicine Pub Date : 2025-03-18 eCollection Date: 2025-04-01 DOI:10.1016/j.eclinm.2025.103151
Kogieleum Naidoo, Nonhlanhla Yende Zuma, Mikaila Moodley, Felix Made, Rubeshan Perumal, Santhanalakshmi Gengiah, Jacqueline Ngozo, Nesri Padayatchi, Andrew Nunn, Salim Abdool Karim
{"title":"获得初级保健设施的结核病患者的高死亡率:来自一项开放标签聚类随机试验的二次分析","authors":"Kogieleum Naidoo, Nonhlanhla Yende Zuma, Mikaila Moodley, Felix Made, Rubeshan Perumal, Santhanalakshmi Gengiah, Jacqueline Ngozo, Nesri Padayatchi, Andrew Nunn, Salim Abdool Karim","doi":"10.1016/j.eclinm.2025.103151","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) mortality remains persistently high, despite global TB control efforts. The aim of this study was to assess if a quality improvement (QI) intervention reduced deaths in TB patients accessing primary healthcare (PHC) services.</p><p><strong>Methods: </strong>In this pre specified secondary analysis of a cluster-randomized controlled study conducted in 2016-2018 in South Africa (Clinicaltrials.gov, NCT02654613), we compared 18-month case-fatality rates among newly diagnosed TB patients irrespective of HIV status randomized to clinics receiving the QI intervention and standard of care (SOC) [(eight clusters and 20 clinics per arm)]. Statistical inferences used a <i>t</i>-test from a two-stage approach recommended for cluster-randomized trials with fewer than 15 clusters per arm.</p><p><strong>Findings: </strong>Among the 5817 newly diagnosed TB patients enrolled (intervention = 3473; control = 2344), 562 died by 18-months [case-fatality rate (CFR) = 9·7%]. Ninety percent of the deaths (506/562) occurred within six months of TB treatment initiation. Quality improvement intervention arm clinics compared to control arm clinics did not demonstrate a significant difference in TB CFR. Case-fatality rates were 9·5% [95% Confidence Interval (CI): 6·9-12·9] and 11·3% (95% CI: 8·7-14·7) [adjusted rate ratio (aRR), 0·9 (95% CI: 0·6-1·2)] in the intervention and control arms, respectively. In people living with HIV/AIDS (PLWHA) CFR in the intervention and control arms: were 10·8% (95% CI: 7·8-14·7) and 14·4% (95% CI: 9·3-22·4) in those on antiretroviral therapy (ART) and 18·6 (95% CI: 9·1-38·0) and 33·0 (95% CI: 16·2-67·3), in those with no ART data respectively. In the intervention and control arms CFR in HIV-TB coinfected patients was 6·5 (95% CI: 3·6-11·6) and 11·5 (95% CI: 6·5-20·0) in those on ART with viral loads <200 copies/ml and 22·4 (95% CI: 16·7-30·2) and 19·7 (95% CI: 11·3-34·5) in those with no viral load data as they commenced ART within 12 months before initiating TB treatment, respectively.</p><p><strong>Interpretation: </strong>The quality improvement intervention did not significantly reduce mortality. <i>We observed that TB CFR was higher among PLWHA not on ART and HIV-TB coinfected patients.</i></p><p><strong>Funding: </strong>Research reported in this publication was supported by South African Medical Research Council (SAMRC), and UK Government's Newton Fund through United Kingdom Medical Research Council (UKMRC).</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"82 ","pages":"103151"},"PeriodicalIF":9.6000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957806/pdf/","citationCount":"0","resultStr":"{\"title\":\"High mortality among patients with tuberculosis accessing primary care facilities: secondary analysis from an open-label cluster-randomised trial.\",\"authors\":\"Kogieleum Naidoo, Nonhlanhla Yende Zuma, Mikaila Moodley, Felix Made, Rubeshan Perumal, Santhanalakshmi Gengiah, Jacqueline Ngozo, Nesri Padayatchi, Andrew Nunn, Salim Abdool Karim\",\"doi\":\"10.1016/j.eclinm.2025.103151\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Tuberculosis (TB) mortality remains persistently high, despite global TB control efforts. The aim of this study was to assess if a quality improvement (QI) intervention reduced deaths in TB patients accessing primary healthcare (PHC) services.</p><p><strong>Methods: </strong>In this pre specified secondary analysis of a cluster-randomized controlled study conducted in 2016-2018 in South Africa (Clinicaltrials.gov, NCT02654613), we compared 18-month case-fatality rates among newly diagnosed TB patients irrespective of HIV status randomized to clinics receiving the QI intervention and standard of care (SOC) [(eight clusters and 20 clinics per arm)]. Statistical inferences used a <i>t</i>-test from a two-stage approach recommended for cluster-randomized trials with fewer than 15 clusters per arm.</p><p><strong>Findings: </strong>Among the 5817 newly diagnosed TB patients enrolled (intervention = 3473; control = 2344), 562 died by 18-months [case-fatality rate (CFR) = 9·7%]. Ninety percent of the deaths (506/562) occurred within six months of TB treatment initiation. Quality improvement intervention arm clinics compared to control arm clinics did not demonstrate a significant difference in TB CFR. Case-fatality rates were 9·5% [95% Confidence Interval (CI): 6·9-12·9] and 11·3% (95% CI: 8·7-14·7) [adjusted rate ratio (aRR), 0·9 (95% CI: 0·6-1·2)] in the intervention and control arms, respectively. In people living with HIV/AIDS (PLWHA) CFR in the intervention and control arms: were 10·8% (95% CI: 7·8-14·7) and 14·4% (95% CI: 9·3-22·4) in those on antiretroviral therapy (ART) and 18·6 (95% CI: 9·1-38·0) and 33·0 (95% CI: 16·2-67·3), in those with no ART data respectively. In the intervention and control arms CFR in HIV-TB coinfected patients was 6·5 (95% CI: 3·6-11·6) and 11·5 (95% CI: 6·5-20·0) in those on ART with viral loads <200 copies/ml and 22·4 (95% CI: 16·7-30·2) and 19·7 (95% CI: 11·3-34·5) in those with no viral load data as they commenced ART within 12 months before initiating TB treatment, respectively.</p><p><strong>Interpretation: </strong>The quality improvement intervention did not significantly reduce mortality. <i>We observed that TB CFR was higher among PLWHA not on ART and HIV-TB coinfected patients.</i></p><p><strong>Funding: </strong>Research reported in this publication was supported by South African Medical Research Council (SAMRC), and UK Government's Newton Fund through United Kingdom Medical Research Council (UKMRC).</p>\",\"PeriodicalId\":11393,\"journal\":{\"name\":\"EClinicalMedicine\",\"volume\":\"82 \",\"pages\":\"103151\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11957806/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EClinicalMedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.eclinm.2025.103151\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2025.103151","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:尽管全球努力控制结核病,但结核病死亡率仍然居高不下。本研究的目的是评估质量改善(QI)干预是否降低了获得初级卫生保健(PHC)服务的结核病患者的死亡率。方法:在2016-2018年在南非进行的一项预先指定的集群随机对照研究的二级分析中(Clinicaltrials.gov, NCT02654613),我们比较了新诊断的结核病患者的18个月病死率,而不考虑HIV状态,随机分配到接受QI干预和标准护理(SOC)的诊所[8个集群,每组20个诊所]。统计推断使用两阶段方法的t检验,推荐用于每组少于15组的群集随机试验。结果:入组的5817例新诊断结核病患者中(干预= 3473;对照组2344例),18个月死亡562例[病死率(CFR) = 9.7%]。90%的死亡(506/562)发生在开始结核病治疗的6个月内。质量改进干预组诊所与对照组诊所相比,在TB CFR方面没有显着差异。干预组和对照组的病死率分别为9.5%[95%可信区间(CI): 6.9 - 12.9]和11.3% (95% CI: 8.7 - 14.7)[调整后的病死率比(aRR)为0.9 (95% CI: 0.6 - 2)]。在艾滋病毒/艾滋病感染者(PLWHA)中,干预组和控制组的CFR在接受抗逆转录病毒治疗(ART)的患者中分别为10.8% (95% CI: 7.8 - 14.7)和14.4% (95% CI: 9.3 - 22.4),在没有抗逆转录病毒治疗数据的患者中分别为18.6% (95% CI: 9.1 - 38.0)和33.0 (95% CI: 16.2 - 67.3)。在干预组和对照组中,HIV-TB合并感染患者的CFR分别为6.5 (95% CI: 3.6 - 11.6)和11.5 (95% CI: 6.5 - 20.0)。解释:质量改善干预并没有显著降低死亡率。我们观察到未接受抗逆转录病毒治疗的艾滋病患者和HIV-TB合并感染患者的结核病CFR更高。资助:本出版物中报告的研究得到了南非医学研究理事会(SAMRC)和英国政府牛顿基金通过英国医学研究理事会(UKMRC)的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
High mortality among patients with tuberculosis accessing primary care facilities: secondary analysis from an open-label cluster-randomised trial.

Background: Tuberculosis (TB) mortality remains persistently high, despite global TB control efforts. The aim of this study was to assess if a quality improvement (QI) intervention reduced deaths in TB patients accessing primary healthcare (PHC) services.

Methods: In this pre specified secondary analysis of a cluster-randomized controlled study conducted in 2016-2018 in South Africa (Clinicaltrials.gov, NCT02654613), we compared 18-month case-fatality rates among newly diagnosed TB patients irrespective of HIV status randomized to clinics receiving the QI intervention and standard of care (SOC) [(eight clusters and 20 clinics per arm)]. Statistical inferences used a t-test from a two-stage approach recommended for cluster-randomized trials with fewer than 15 clusters per arm.

Findings: Among the 5817 newly diagnosed TB patients enrolled (intervention = 3473; control = 2344), 562 died by 18-months [case-fatality rate (CFR) = 9·7%]. Ninety percent of the deaths (506/562) occurred within six months of TB treatment initiation. Quality improvement intervention arm clinics compared to control arm clinics did not demonstrate a significant difference in TB CFR. Case-fatality rates were 9·5% [95% Confidence Interval (CI): 6·9-12·9] and 11·3% (95% CI: 8·7-14·7) [adjusted rate ratio (aRR), 0·9 (95% CI: 0·6-1·2)] in the intervention and control arms, respectively. In people living with HIV/AIDS (PLWHA) CFR in the intervention and control arms: were 10·8% (95% CI: 7·8-14·7) and 14·4% (95% CI: 9·3-22·4) in those on antiretroviral therapy (ART) and 18·6 (95% CI: 9·1-38·0) and 33·0 (95% CI: 16·2-67·3), in those with no ART data respectively. In the intervention and control arms CFR in HIV-TB coinfected patients was 6·5 (95% CI: 3·6-11·6) and 11·5 (95% CI: 6·5-20·0) in those on ART with viral loads <200 copies/ml and 22·4 (95% CI: 16·7-30·2) and 19·7 (95% CI: 11·3-34·5) in those with no viral load data as they commenced ART within 12 months before initiating TB treatment, respectively.

Interpretation: The quality improvement intervention did not significantly reduce mortality. We observed that TB CFR was higher among PLWHA not on ART and HIV-TB coinfected patients.

Funding: Research reported in this publication was supported by South African Medical Research Council (SAMRC), and UK Government's Newton Fund through United Kingdom Medical Research Council (UKMRC).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信